✦ LIBER ✦

Acute dystonia after injection of pegylated interferon alpha-2b

✍ Scribed by Lucas C. Quarantini; Angela Miranda-Scippa; Raymundo Parana; Aline Santos Sampaio; Rodrigo A. Bressan

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 48 KB
Volume: 22
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.21302

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparative effects of interferon alpha-

Comparative effects of interferon alpha-2b and pegylated interferon alpha-2b on menstrual cycles and ovarian hormones in cynomolgus monkeys

✍ Brian P. Enright; David R. Compton; Nathaniel Collins; Thomas Davis; Barry S. Mc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 782 KB

Early monotherapy with pegylated interfe

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study

✍ Johannes Wiegand; Peter Buggisch; Wulf Boecher; Stefan Zeuzem; Cornelia M. Gelbm 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Early treatment of acute hepatitis C with interferon alpha-2b for 24 weeks prevents chronic infection in almost all patients. Because pegylated interferons have replaced conventional interferon in the therapy of chronic hepatitis C, the aim of this study was to analyze the efficacy of an early treat

Treatment of chronic hepatitis E in live

Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b

✍ Elizabeth B. Haagsma; Annelies Riezebos-Brilman; Arie P. van den Berg; Robert J. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

Hepatitis E virus (HEV) infections are known to run a self-limiting course. Recently, chronic hepatitis E has been described in immunosuppressed patients after solid-organ transplantation. Besides the general recommendation to lower the immunosuppressive medication in these patients, there is curren

Treatment of acute non-A, non-B hepatiti

Treatment of acute non-A, non-B hepatitis with interferon alpha-2b

✍ N. C. Tassopoulos; Maria Koutelou; G. Papatheodoridis; Th. Giannikakis; Melpomen 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 192 KB

Association of IL28B variants with respo

Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b

✍ Naoya Sakamoto; Mina Nakagawa; Yasuhito Tanaka; Yuko Sekine-Osajima; Mayumi Ueya 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated‐interferon (PEG‐IFN) plus ribavirin (RBV) combination therapy. The aim of this study was to investigate the relationship between IL28B polymorphism and responses to therapy in pa

Pegylated interferon alpha-2b plus ribav

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response

✍ Sanaa M. Kamal; Samer S. El Kamary; Michelle D. Shardell; Mohamed Hashem; Imad N 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 2 views

In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined. In this study, 358 patients with chronic hepatitis C genotype 4 were randomly assigned to pegylated